Harrison College of Pharmacy

Faculty and Staff Directory

---

---

Bio

---

Jingjing Qian, Ph.D, is an Associate Professor in the Harrison College of Pharmacy's Department of Health Outcomes Research and Policy.

Research Interests:

My research focuses on health outcomes and pharmacoepidemiology research, particularly with regards to comparative effectiveness and safety of drug products. The goal of my research is to provide effective strategies and interventions to improve population health and eliminate health disparities. My research has involved in promoting generic drug post-marketing surveillance and education with collaboration from off campus partners supported by multiple U.S. FDA grants. Currently I am focusing on cancer epidemiology, prevention, and comparative effectiveness of treatments among patients with breast, prostate, and lung cancer. Additional research interests include mental health, substance use disorders, and disability research, treatment optimization and outcomes for patients with chronic conditions, medication adherence, and quality of care among vulnerable populations.

---

Currently Funded Research:

1/1/25 – 5/31/26: American Foundation for Pharmaceutical Education
Safety of Homeopathic Drug Products. Total cost $30,888
Role: PI

---

Completed Funded Research:

1/1/22 – 12/31/22: Breast Cancer Research Foundation of Alabama
Improving Breast Cancer Survival in Alabama - The Role of Medicines. Total cost $49,529
Role: PI

1/1/21 – 12/31/21: Breast Cancer Research Foundation of Alabama
Breast Cancer Research Foundation of Alabama. Total cost $30,334
Role: PI

7/1/18 – 6/30/21: Oregon Health & Science University
Data Analysis and Summary Documents for the Drug Effectiveness Review Project (DERP). Total cost $500,000
Role: Co-PI

1/1/20 – 12/31/20: Mike Slive Foundation
Impact of Cognitive Function on Treatment Selection and Outcomes of among Older Patients with Prostate Cancer. Total cost $50,000
Role: PI

9/15/15 – 2/28/19: U.S. Food and Drug Administration (Grant# U01FD005486)
Educating Groups Influencing Generic Drug Use. Total cost $749,837
Role: PI

9/30/15 – 9/29/18: U.S. Food and Drug Administration (Grant# FDA BAA-13-0019)
Comparative Surveillance of Generic Drugs by Machine Learning. Total cost $2,500,000
Role: Co-Investigator; PI: Peissig

9/05/16 – 8/31/18: U.S. Food and Drug Administration (Grant# U01FD005875)
Generic Drug Substitution in Special Populations. Total cost $399,990
Role: PI

---

Selected Publications:

Xue X, Loop M, Johnson B, Ngorsuraches S, Zheng J, Qian J. Comparative Real-World Survival of First-Line Atezolizumab, Nivolumab, and Pembrolizumab in Older Patients with Metastatic Non-Small Cell Lung Cancer. J Manag Care Spec Pharm. 2025 Nov;31(11):1123-1134

Ezeja L, Qian J. Post-marketing Safety of Lantus and Its Interchangeable Biosimilar Semglee in the United States: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) Database. Diabetes Obes Metab. 2025 Aug;27(8):4480-4489

Qian J, Xue X, Ezeja L, Boxx Z, Jackson C. Post-Marketing Safety of Antiseizure Medications: Focus on Serious Adverse Effects including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Seizure. 2025 Feb:125:37-43

Yue Z, Jaradat S, Qian J. Prediction of Cognitive Impairment among Medicare Beneficiaries Using a Machine Learning Approach. Arch Gerontol Geriatr. 2025 Jan:128:105623

Truong B, Hornsby L, Fox B, Chou C, Zheng J, Qian J. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from Seer-Medicare Database. Cardiovasc. Drugs Ther. 2025 Aug;39(4):823-835

Qian J, Truong B. Early Initiation and 1-Year Adherence to Oral Endocrine Therapy and Survival Benefit among Female Medicare Beneficiaries with Early-stage Breast Cancer. J Womens Health. 2024 Nov;33(11):1509-1517

Xue X, Qian J. Safety of Marketed Biosimilar Monoclonal Antibody Cancer Treatments in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Expert Opin Drug Saf. 2024 May 3:1-10

Qian J, Khatiwada AP, Xue X. Did the 2021 Federal Change in the Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder Increase Prescription Dispensing in Medicaid Population? Am J Addict. 2024 May;33(3):335-338

Truong B, Hornsby L, Fox B, Chou C, Zheng J, Qian J. Screening for Clinically Relevant Drug-Drug Interactions between Direct Oral Anticoagulants and Antineoplastic Agents: A Pharmacovigilance Approach. J Thromb Thrombolysis. 2023 Nov;56(4):555-567

Zou C, Xue X, Qian J. Characteristics and Comparison of Adverse Events of COVID-19 Vaccines Reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) Between December 14, 2020, and October 8, 2021. Front Med. 2022 Apr 5;9:826327

Truong B, Tanni K, Qian J. Video-Observed Therapy versus Directly-Observed Therapy in Tuberculosis Patients. Am J Prev Med. 2022 Mar;62(3):450-458

Qian J, Li C, Truong B. Physical Function Before and After Initial Treatment among Older Adults with Localized or Regional Stage Prostate Cancer. J Geriatr Oncol. 2022 Jan;13(1):104-107

Tanni K, Truong B, Johnson B, Qian J. Comparative Effectiveness and Safety of Eribulin in Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Crit Rev Oncol Hematol. 2021 Jul;163:103375

Li C, Ngorsuraches S, Chou C, Chen L, Qian J. Risk Factors of Fluoropyrimidine Induced Cardiotoxicity Among Cancer Patients: A Systematic Review and Meta-analysis. Crit Rev Oncol Hematol. 2021 Jun;162:103346

Tanni K, Truong B, AlMahasis S, Qian J. Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. BioDrugs. 2021 Mar;35(2):239-254

Qian J. Uptake and Cost of Biosimilar Filgrastim among the Medicare and Medicaid Populations in 2015-2018. J Manag Care Spec Pharm. 2021 May;27(5):660-666
Zeng Z, Mishuk AU, Qian J. Safety of Dietary Supplements Use among Patients with Cancer: A Systematic Review. Crit Rev Oncol Hematol. 2020 Aug;152:103013
Mishuk AU, Fasina I, Qian J. Impact of U.S. Federal and State Generic Drug Policies on Drug Use, Spending, and Patient Outcomes - A Systematic Review. Res Social Adm Pharm. 2020 Jun;16(6):736-745

Qian J, Mishuk AU, Hansen RA. Does Public Perception Bias Lead to More Frequent Reporting of Adverse Events: Branded vs Generic Drugs. Expert Opin Drug Saf. 2018 Aug;17(8):753-756

Hohmann N, Hansen RA, Garza KB, Harris I, Kiptanui Z, Qian J. Association between Higher Generic Drug Use and Medicare Part D Prescription Plan Star Ratings: an Observational Analysis. Value Health. 2018 Oct;21(10):1186-1191

Li C, Hansen RA, Chou C, Calderón AI, Qian J. Trends in botanical dietary supplement use among US adults by cancer status: The National Health and Nutrition Examination Survey, 1999 to 2014. Cancer. 2018 Mar 15;124(6):1207-1215.

---

Teaching:

HORP 7530 Pharmaceutical Economics, Outcomes, and Policy (Fall)
HORP 7540 Pharmacoepidemiology (Spring)
HORP 7820 Research Methods for the Health Sciences (Fall)
HORP 7950/8950 Graduate Seminar (Fall/Spring)
PYPD-9330 Longitudinal 2 (Spring)
PYPD-9360 Longitudinal 5 (Fall)

---

Recent and Current Graduate Students:

Sara Jaradat (PhD)
Lotanna Ezeja (PhD)
Xiangzhong Xue (PhD) Kaniz Afroz Tanni (PhD)
Bang Truong (Ph.D., 2023)
Kaniz Afroz Tanni (Ph.D., 2023)
Chao Li (Ph.D., 2021)
Ahmed Ullah Mishuk (Ph.D., 2021)
Nan Huo (Ph.D., 2019)
Saranrat Wittayanukorn, MS (Ph.D., 2015)

---